A further phase IIb doubleblind RCT evaluating the safety and efficacy of BMS-986036 (PEG-FGF21) in adults with NASH and stage 3 liver fibrosis (FALCON1, ClinicalTrials. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.